
    
      This multicenter study has 2 parts and is designed to provide data in Japanese participants,
      as required for registration of natalizumab (BG00002) in Japan. Part A will consist of an
      open-label cohort of 12 participants who will receive 300 mg natalizumab intravenously (IV)
      every 4 weeks over a 6-month treatment period. Part B will consist of a double-blind,
      placebo-controlled cohort of approximately 90 participants randomized in a ratio of 1:1 to
      receive IV infusions of placebo or 300 mg BG00002 every 4 weeks over a 6-month period.
    
  